$BMSN Company News 10-Q: BIO-MATRIX SCIENTIFIC
Post# of 94143
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 9:40 a.m. May 13, 2014 - Edgar Online - (EDG = 10Q, 10K)
Regen Bio provides an update on IND 1:52 p.m. May 12, 2014 - Seeking Alpha
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 7:10 p.m. Feb. 6, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-K: BIO-MATRIX SCIENTIFIC GROUP, INC. 3:51 p.m. Jan. 7, 2014 - Edgar Online - (EDG = 10Q, 10K)
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 12:52 p.m. Aug. 14, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 2:00 p.m. July 31, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-K/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 11:02 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 10:49 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q/A: BIO-MATRIX SCIENTIFIC GROUP, INC. 10:42 a.m. June 21, 2013 - Edgar Online - (EDG = 10Q, 10K)
10-Q: BIO-MATRIX SCIENTIFIC GROUP, INC. 1:07 p.m. May 17, 2013 - Edgar Online - (EDG = 10Q, 10K)
Bio-Matrix Scientific Group Inc. Subsidiary Regen BioPharma Inc. Collaborates on Research Paper Analyzing the Use of Gene Silencing in Heart Transplants 10:01 a.m. June 11, 2014 - Marketwire
Bio-Matrix Scientific Group, Inc. Sees 37% Increase In Share Price 10:52 a.m. May 13, 2014 - ACCESSWIRE
Regen BioPharma, a Majority Owned Subsidiary of Bio-Matrix Scientific Group, Provides Update on HemaXellerate I(TM) IND for Treatment of Drug Resistant Aplastic Anemia 12:32 p.m. May 12, 2014 - Marketwire
Bio-Matrix Scientific Group Inc. Announces Dividend Record Date to Receive Shares in Its Subsidiary Regen BioPharma, Inc. 3:54 p.m. March 6, 2014 - Marketwire
Regen BioPharma Announces HemaXellerate I(TM) Efficacy Data in Animal Model of Aplastic Anemia 10:35 a.m. Dec. 11, 2013 - Marketwire
Bio-Matrix Scientific Group's Regen BioPharma Retains Cook General Biotechnology for Contract Manufacturing of HemaXellerate I 11:36 a.m. Oct. 31, 2013 - Marketwire
New In-Depth Stock Reports on BMSN, CERP, NAMG and NVIV 1:03 a.m. Oct. 25, 2013 - ACCESSWIRE
Bio-Matrix Scientific Group Inc. Announces 20 Million Share Regen BioPharma Dividend to Be Paid to Shareholders 3:12 p.m. Oct. 9, 2013 - Marketwire
Bio-Matrix Scientific Group's Subsidiary Regen BioPharma Enters Into Preclinical Trials Agreement for HemaXellerate I Covering Aplastic Anemia 8:01 a.m. Sept. 26, 2013 - Marketwire
Bio-Matrix Scientific Group's Subsidiary, Regen BioPharma Announces dCellVax Breast Cancer Immunotherapeutic Product 8:31 a.m. Sept. 25, 2013 - Marketwire
Bio-Matrix Scientific Group Recruits RNA Interference Pioneer Dr. David Suhy to Regen BioPharma Inc.'s Scientific Advisor Board 10:07 a.m. Sept. 17, 2013 - Marketwire
Bio-Matrix Scientific Group Discusses Regen BioPharma's Cancer Immunotherapy Program 1:49 p.m. Aug. 16, 2013 - Marketwire
Regen BioPharma Inc. Licenses Cancer Gene Silencing Technology From Benitec BioPharma 9:48 a.m. Aug. 8, 2013 - Marketwire
Bio-Matrix Scientific Group Provides Update on Its Regen BioPharma's HemaXellerate I(TM) Clinical Program 2:37 p.m. July 31, 2013 - Marketwire
Bio-Matrix Scientific Group's Regen BioPharma Submits Response to FDA Questions Regarding HemaXellerate Clinical Program 8:30 a.m. June 7, 2013 - Marketwire